Global ETD Search

1	EGFR阻害薬GefitinibおよびErlotinibによるeIF2αのリン酸化に関する研究小山, 智志 23 March 2016 (has links) 京都大学 / 0048 / 新制・課程博士 / 博士(薬学) / 甲第19654号 / 薬博第824号 / 新制\|\|薬\|\|240(附属図書館) / 32690 / 京都大学大学院薬学研究科薬学専攻 / (主査)教授松原和夫, 教授中山和久, 教授金子周司 / 学位規則第4条第1項該当 / Doctor of Pharmaceutical Sciences / Kyoto University / DFAM EGFR inhibitor Interstitial lung disease eIF2α cyclin D1 TUDCA 499
2	Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells / 上皮様および間葉様食道扁平上皮癌細胞に対する、EGFR阻害剤の相異なる作用 Yoshioka, Masahiro 23 January 2018 (has links) 京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20795号 / 医博第4295号 / 新制\|\|医\|\|1025(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授原田浩, 教授松原和夫, 教授坂井義治 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM Esophageal squamous cell carcinoma EGFR inhibitor Cell differentiation Epithelial-like cell Mesenchymal-like cell 490
3	Exploitation and Mechanistic Validation of Drug-combination Strategies to Overcome EGFR-inhibitor resistance in NSCLC cells Wang, Yu-Chieh January 2008 (has links) No description available. Oncology non-small cell lung cancer EGFR inhibitor HDAC inhibitor Akt ER stress NR4A1
4	The effects of various combinations of different Cdasses of anticancer drugs and tyrosine kinase inhibitors on the human MCF-7 and triple-negative MDA-MB 231 breast carcinoma cell lines Abrahams, Beynon January 2020 (has links) Philosophiae Doctor - PhD / Globally, breast cancer is the most common cancer affecting women and it is predicted that in 2030 about 12 million deaths will occur with approximately 21.7 million new cases [2]. Genetic risk factors as well as race and ethnicity, account for about 5-10% of all breast cancer occurrences. Triple negative breast cancer (TNBC), tumors that tested negative for oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), contribute to 10-20% of all breast carcinomas [3,4] and is known to be a more aggressive type of cancer with varying degree of response to chemotherapeutic and radiation therapy [5,6] / 2022-02-24 Breast cancer MCF-7 breast carcinoma cells MDA-MB-231 TNBC cells Tyrosine kinase inhibitor EGFR inhibitor
5	The effects of various combinations of different classes of anticancer drugs and tyrosine kinase inhibitors on the human MCF-7 breast carcinoma cell line Abrahams, Beynon January 2014 (has links) Magister Scientiae (Medical Bioscience) - MSc(MBS) / This study investigated the effects of TKIs on the growth and proliferation of MCF-7 breast carcinoma cells in culture. MCF-7 cells were exposed to different concentrations of TKIs alone and in combination with each other. Inhibition of cell growth by TKIs used individually occurred in a dose- and time-dependent manner. When EGFR Inhibitor I, EGFR Inhibitor II/BIBX1382 and the multi-specific EGFR/ErbB-2/ErB-4 Inhibitor were used in combination with each other at equimolar log dose concentrations, the combined effects on cell growth was significantly different to inhibitors used individually as reflected in a decreased EC50 (IC50) during combination treatments. Generally, for the combinations with DOX, CPL and the TKIs, synergistic as well as antagonistic effects were observed at isoeffective concentrations with resultant decreases in dose reduction indices (DRIs) implying greater efficacies with the respective combinations. In this study, conventional PCR was used to detect and illustrate the presence of the EGFR gene in the samples, while RT-qPCR was used to determine the mRNA expression levels of this gene in MCF-7 breast carcinoma cells Breast cancer Human MCF-7 breast carcinoma cells Epidermal growth factor receptor Tyrosine kinase inhibitors Doxorubicin Cisplatin EGFR inhibitor I EGFR inhibitor II/BIBX1382 EGFR/ErbB2/ErbB4 inhibitor Dose-response curves IC50/EC50 Drug combination analysis Synergism Antagonism Dose-reduction indices Haematoxylin and eosin staining Annexin V-Cy3 fluorescent staining Apoptosis EGFR gene expression analysis Real-time qPCR

1

Page generated in 0.0535 seconds